Felix Garzon MD, PH.D.: Record of Success Strengthens Team as Company Prepares for the Iomab-B Pivotal Trial
NEW YORK, NY--(August 18, 2015) - Actinium Pharmaceuticals, Inc. ($ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the appointment of Felix Garzon, MD, Ph.D. to the position of Senior Vice President, Head of Clinical Development effective August 17, 2015. Dr. Garzon brings with him 28 years of pertinent pharmaceutical and biotechnology experience in increasingly senior roles, most recently at Eisai and Bristol-Myers Squibb, having worked on both later and earlier stages of drug development.
"Felix's deep expertise in hematology and oncology drug development will strengthen the Actinium team in an important way. He brings to Actinium a rigorous track record of successful clinical development in diverse settings including leadership roles with international product teams in large and small companies and in different therapeutic indications," said Kaushik J. Dave, Ph.D., Chief Executive Officer of Actinium Pharmaceuticals. "In addition, Felix has significant clinical trial management and regulatory experience. All of these are key skills as we ramp up our preparations for the upcoming trials for Iomab-B and Actimab-A."
Dragan Cicic, MD, Chief Medical Officer of Actinium added, "Felix is a great addition to our team, whose vast experience in and focus on hematologic oncology will enable us to execute our ambitious programs in a timely and precise manner."
"I am very excited to join the Actinium organization," said Dr. Garzon. "Actinium is pursuing breakthroughs in the field in which I have more than a quarter of a century of professional experience. With two very promising products poised to enter Phase 3 and Phase 2 trials, I am thrilled to have an opportunity to maximize the development prospects for Iomab-B and Actimab-A. As we build and strengthen the clinical team to meet milestones, I look forward to adding value by generating high quality clinical data to help achieve timeline objectives."
Dr. Garzon has more than 28 years of robust international experience working in positions of increasing responsibility in the development of new oncology and hematology drugs in several successful companies in the United States and Europe. He has successfully led and managed the late development and approval of several anticancer drugs, including Halaven®, Trisenox® and Xyotax®. Other roles included Clinical Lead at a Product Creation Unit, Head of Medical Affairs and strategic development plan creation and implementation. Prior to his extensive work in oncology drug development for the pharmaceutical industry, he worked as a scientist in the research of new anti-cancer drugs for several years at the Institute of Toxicology & Chemotherapy of the German Cancer Research Centre, Heidelberg, Germany. Dr. Garzon is the author and co-author of over 80 relevant scientific publications, abstracts and presentations given at international scientific meetings.
Dr. Garzon was previously Senior Director, Oncology Product Creation Unit at Eisai, and Director, Oncology Global Clinical Research at Bristol-Myers Squibb. He also had roles at Chiron, Cell Therapeutics, Rhône-Poulenc Rorer, Pharmacia & Upjohn and Ipsen, following academic appointments and education in Germany, France and Argentina.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
David Gould, MD
SVP, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer